4.1K Views 2 years ago

FDA Modernization Act 3.0 Introduced to Reform Animal Testing

A bipartisan group of lawmakers in the House introduced the FDA Modernization Act 3.0 on February 6, 2024. The bill aims to push the U.S. Food and Drug Administration (FDA) to implement the FDA Modernization Act 2.0, a law passed in the 117th Congress.

The FDA Modernization Act 2.0, enacted at the close of 2022, marked a pivotal moment by eliminating a long-standing animal-testing mandate used since the Depression era. This repeal granted drug sponsors the option to employ innovative 21st-century, human-biology-based methods instead of traditional animal testing.

The proposed legislation, FDA Modernization Act 3.0, mandates the FDA to finalize rules for implementing FDAMA 2.0. It seeks to establish clear guidelines for non-animal test methods that better predict drug safety and efficacy. By doing so, the bill aims to expedite the time to market for new treatments and cures, benefiting both patients and drug sponsors.

Leading the charge on this bipartisan effort are U.S. Representatives Buddy Carter (R-Ga.), Nanette Barragán (D-Cal.), Diana Harshbarger (R-Tenn.), and Rosa DeLauro (D-Conn.). These legislators, along with other supporters, emphasize the urgent need for the FDA to embrace modern, human-relevant models in drug development, sparing countless animals from needless torment.

The push for FDA Modernization Act 3.0 underscores a critical shift towards more ethical and effective drug testing methodologies. Representative Buddy Carter said, “The FDA Modernization Act 3.0 will allow for the development of safe, effective treatments and therapies without unnecessary animal suffering. We have a law allowing for animal-free testing methods on the books, and it’s time we put it to use by expanding testing options.”

Echoing this sentiment is Representative Nanette Barragán saying, “Every animal should be treated humanely and not be subjected to cruel laboratory testing methods for human drug development. A stronger implementation of the FDA Modernization Act 2.0 will not only Support alternatives for more humane drug testing, but also Support more safe and effective delivery of drugs to patients. As an animal lover, I am proud to lead this bipartisan effort with Rep. Carter to reduce practices of animal testing for drug development.”

Support for the FDA Modernization Act extends beyond Capitol Hill. Dr. Zaher Nahle, Senior Scientific Advisor for the Center for a Humane Economy and Animal Wellness Action, reveals the potential for a paradigm shift in drug development. He advocates for embracing innovative, human-relevant models to break the logjam in medical innovation.

With widespread Support from animal welfare groups, biotech and pharmaceutical companies, and patient advocacy organizations, the FDA Modernization Act represents a pivotal moment in advancing humane drug development practices. Senators Rand Paul (R-Ky.), Cory Booker (D-N.J.), and Mike Braun (R-Ind.) led the Senate bill, underscoring bipartisan recognition of the urgent need for change.